TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07858019: A Two-part, Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered COR-2003, as Mono

Sponsor: Corsera Health · Phase: PHASE1 · Area: RARE_ORPHAN · Target Enrollment: 108 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,206,400

Rescue Site Savings

+$7,389,220

Unlock Full NCT07858019 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07858019 Rescue Dossier →